SGS Opens Three New Offices
SGS Opens Central & Eastern Europe Offices for Clinical Trial Management.
Geneva, Switzerland-April 25, 2008-As a further step in the initiative to expand its Global Clinical Development (GCD) services, SGS Life Science Services has opened three new offices in Poland, Czech Republic, and Romania. The offices located in Prague, Warsaw, and Bucharest, respectively, will provide services for clinical trial monitoring, study feasibility, and site selection, as well as support the regulatory aspects in these countries.
“The opening of the new offices addresses the request of many of our sponsors to conduct trials in Central and Eastern Europe in order to benefit from the vast pool of treatment naïve patients, faster enrolment times, and the cost benefits these countries offer,” said Luc Braeken, vice president of global clinical development. “Highly qualified and motivated investigators, low drop out rates of enrolled patients, and the high quality of the clinical data are additional advantages of conducting trials in Central and Eastern Europe.”
The offices are staffed with highly knowledgeable teams with broad experience in conducting clinical trials in the pharmaceutical and CRO industry as well as in academia. Lead by seasoned MDs, the teams cover a wide range of therapeutic areas with special emphasis in CNS, infectious disease, and cardiovascular disease, SGS’ areas of core expertise.Complementary services including project management, data management and statistics, regulatory affairs, and medical affairs will be provided from SGS’ main office for GCD in Belgium with more than 400 people.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025